María Gómez‐Cañas

A Cannabigerol Quinone Alleviates Neuroinflammation in a Chronic Model of Multiple Sclerosis

Aitor G. Granja, Francisco J. Carrillo‐Salinas, Alberto Pagani et al. · Journal of Neuroimmune Pharmacology · 2012 · 154 citations

Neurological Disorder, Medicine, Neuropharmacology +9

Prenatal exposure to cannabinoids evokes long-lasting functional alterations by targeting CB ₁ receptors on developing cortical neurons

Adán de Salas-Quiroga, Javier Díaz-Alonso, Daniel García-Rincón et al. · Proceedings of the National Academy of Sciences · 2015 · 152 citations · Full text

Targeting CB2-GPR55 Receptor Heteromers Modulates Cancer Cell Signaling

Estefanía Moreno, Clara Andradas, Mireia Medrano et al. · Journal of Biological Chemistry · 2014 · 113 citations · Full text

Functional Selectivity, Medicine, Cancer Cell Biology +4

The cannabinoid quinol VCE-004.8 alleviates bleomycin-induced scleroderma and exerts potent antifibrotic effects through peroxisome proliferator-activated receptor-γ and CB2 pathways

Carmen del Río, Carmen Navarrete, Juan A. Collado et al. · Scientific Reports · 2016 · 90 citations · Full text

Benefits of VCE-003.2, a cannabigerol quinone derivative, against inflammation-driven neuronal deterioration in experimental Parkinson’s disease: possible involvement of different binding sites at the PPARγ receptor

Concepción García, María Gómez‐Cañas, Sonia Burgaz et al. · Journal of Neuroinflammation · 2018 · 62 citations · Full text